Technology | May 02, 2012

Spectranetics Receives FDA Approval for Advanced GlideLight Laser Sheath

May 2, 2012 — The Spectranetics Corp. announced U.S. Food and Drug Administration (FDA) approval of the new advanced GlideLight Laser Sheath for removal of cardiac leads. As part of the company’s vision to safely manage every lead, GlideLight delivers more precise control to reduce the force for safe lead extraction.

Spectranetics’ current laser sheath, the SLS II, requires significantly less force to advance than mechanical telescoping sheaths. GlideLight is a major leap forward, requiring 55 percent less force to advance than SLS II.

“Mechanical force is a leading cause of complications during lead extraction,” said Bruce Wilkoff, director of cardiac pacing and tachyarrhythmia devices at Cleveland Clinic and a nonpaid member of Spectranetics’ Medical Advisory Board. “[R]educed force improves the control for safely removing leads. It is particularly important to have control when breaking up tough binding sites.”

“GlideLight has taken us to the next level in lead extraction,” said Charles Kennergren, professor at Sahlgrenska University Hospital in Gothenburg, Sweden, and the first physician to use GlideLight clinically. “I am very impressed with the reduced force and increased control and efficiency that GlideLight has provided me.”

A limited market release of GlideLight will be conducted to gain early experience prior to a broader controlled launch. GlideLight will be the company’s focus at the Heart Rhythm Society meeting in Boston May 9-11.

For more information: www.spectranetics.com


Related Content

News | EP Lab

July 31, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home July 31, 2024
Home
News | EP Lab

July 17, 2024 — BioCardia, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of ...

Home July 17, 2024
Home
News | EP Lab

May 30, 2024 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, announced ...

Home May 30, 2024
Home
News | EP Lab

May 21, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home May 21, 2024
Home
News | EP Lab

February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 ...

Home February 02, 2024
Home
News | EP Lab

January 11, 2024 — It is with great sadness that the Diagnostic and Interventional Cardiology (DAIC) team has learned of ...

Home January 11, 2024
Home
News | EP Lab

September 22, 2023 — Innovative Health, Inc. launched a new educational initiative and free online tool to help hospital ...

Home September 22, 2023
Home
News | EP Lab

August 17, 2023 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home August 17, 2023
Home
News | EP Lab

March 28, 2023 — CathVision, a medical technology company developing innovative electrophysiology solutions designed to ...

Home March 28, 2023
Home
Subscribe Now